Fertin Pharma has invested in a wealth of facilities
considered emerging markets for Fertin . At present the company is sitting on a 35 percent of the world market for nicotine gum , and that equates to 90-95 percent of the business . The company also has a 50 percent shareholding in a tableting facility in Vancouver , the focus of which is predominantly dietary supplements for the North American market .
Søren Birn who is CEO of Fertin Pharma , said : “ We have invested heavily in skills , capability and infrastructure so that we have state-of-the-art facilities which produce medicated gum according to cGMP ( current Good Manufacturing Practice ) in three factories , one of which is US FDA-approved .
“ Since we are completely B2B , we of course engage in business development when our
“ We have invested heavily in skills , capability and infrastructure so that we have stateof-the-art facilities ”
– Søren Birn , CEO of Fertin Pharma
www . fertin . com 51